May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
A Comparison of Pegaptanib Sodium and Triamcinolone Acetonide on Choroidal Neovascular Membrane (CNVM) Development in the Rat Laser Trauma Model
Author Affiliations & Notes
  • M.H. Criswell
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • W.–Z. Hu
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • T.J. Steffens
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • R. Li
    QLT Inc., Vancouver, BC, Canada
  • P. Margaron
    QLT Inc., Vancouver, BC, Canada
  • Footnotes
    Commercial Relationships  M.H. Criswell, QLT Inc., F; W. Hu, None; T.J. Steffens, None; R. Li, QLT Inc., E; P. Margaron, QLT Inc., E.
  • Footnotes
    Support  QLT Inc. and an unrestricted grant from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2957. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.H. Criswell, W.–Z. Hu, T.J. Steffens, R. Li, P. Margaron; A Comparison of Pegaptanib Sodium and Triamcinolone Acetonide on Choroidal Neovascular Membrane (CNVM) Development in the Rat Laser Trauma Model . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2957.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Pegaptanib sodium (PS) is a vascular endothelial growth factor (VEGF) antagonist, clinically in use to treat choroidal neovascularization (CNV) caused by age–related macular degeneration. No published reports currently describe the performance of PS in a CNV animal model. This study evaluated the prophylactic effect of intravitreal PS on CNVM development and compared it to the corticosteroid triamcinolone acetonide (TA).

Methods: : After induction of laser trauma sites (75µm diameter), 10 rats in each of 6 designated groups (∼80 sites/group) received either an intravitreal injection (5µL) of: 1) PS 100% (17µg), 2) PS 50% (9µg), 3) PS vehicle (control), 4) TA (200µg), or 5) TA vehicle (control), or received 6) laser only (LO: no injection control). On day 21, fluorescein angiography (FA) was performed at designated times from 1 to 300 sec and late phase (90/180 sec) staining was scored on a 0 low to 3 high scale. CNVM diameters were measured for each site.

Results: : FA revealed no significant differences in mean scores for staining between the PS 100% (x=1.7) and the PS vehicle (1.7), TA vehicle (1.6), or LO (2.0) groups. The PS 50% group score (1.5) also was not significantly different from either PS vehicle or TA vehicle groups, but was significantly (P< .01) lower in comparison to the LO group. The TA score (0.6) was significantly lower compared to all other groups. The CNVM mean diameter for the PS 100% group (176µm) was not significantly different as compared to the PS vehicle (192µm) or TA vehicle (189µm) groups, but was significant (10% reduction; P< .05) to the LO (196µm) group. Comparing the PS 50% group (170µm) to the LO group did represent a small (14%) but statistically significant (P< .01) reduction in mean CNVM diameter, while the TA group (112µm) demonstrated a 43% reduction in CNVM diameter as compared to the LO group and significant differences (P< .01) as compared to all groups.

Conclusions: : Intravitreal PS at the 50% dosage concentration elicited a significant but marginal reduction both in mean CNVM dye–staining and diameter as compared to the LO group only, whereas intravitreal TA resulted in significant and pronounced inhibition of CNVM development as compared to all groups.

Keywords: choroid: neovascularization • growth factors/growth factor receptors • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×